Borderline-resectable pancreatic cancer (BRPC) accounts for nearly 20% of all pancreatic cancer cases diagnosed in the U.S. These tumors are often attached to nearby arteries or veins, making surgery ...

The Details: "We recently reported data from the phase 2 randomized clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care ...

The length of time a person lives after being diagnosed with pancreatic cancer depends on the stage of the cancer; whether the tumor is resectable, borderline, or nonresectable; treatment options ...

In the Company’s randomized phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic cancer, positive survival data showed notable improvement in estimated median overall survival ...

Notable findings include significant improvements in survival rates for patients with localized prostate cancer and borderline resectable pancreatic ductal adenocarcinoma, supporting plans to file ...

localized prostate cancer Recently announced positive final data from randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic ductal adenocarcinoma On track ...

“Her deep expertise in pancreatic cancer and immunotherapy aligns perfectly with our mission, particularly as we advance our CAN-2409 program in borderline resectable pancreatic cancer following ...

NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...